Merck’s Suvorexant To Face FDA Panel Scrutiny On Next-Day Driving Effects
This article was originally published in The Pink Sheet Daily
Executive Summary
The Peripheral and Central Nervous System Drugs Advisory Committee’s May 22 review of the first-in-class insomnia drug will include data from two studies assessing the compound’s residual effects on next-day driving.